ABBV vs MAR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-17.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$334.97
+20.6% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MAR has more upside to fair value
(+20.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MAR |
| Current Price |
$261.70 |
$334.97 |
| Fair Value Estimate |
$259.04 |
$403.81 |
| Upside to Fair Value |
-1.0%
|
+20.6%
|
| Market Cap |
$462.4B |
$87.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
22.2x
|
| Price / Sales |
7.2x
|
3.2x
|
| Price / FCF |
23.6x
|
28.7x
|
| Revenue Growth YoY |
+10.2%
|
+4.8%
|
| Gross Margin |
71.5%
|
20.2%
|
| Operating Margin |
29.3%
|
15.8%
|
| Return on Equity |
-136.5%
|
-66.7%
|
| Dividend Yield |
2.61% |
0.84% |
| FCF Yield |
4.25%
|
3.48%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Marriott International is a global asset-light hotel franchisor and manager whose 10,082-property, 1.814 million-room system, 629,000-room development pipeline, broad brands, and more than 295 million Bonvoy members support durable fee-led economics. Business quality is tempered by cyclicality, competitive owner incentives, and $16.915 billion of debt, while reported ROE is negative 66.7%. In the…
Accumulation Zones
| Metric |
ABBV |
MAR |
| Zone Low |
$194.28 |
$302.86 |
| Zone High |
$220.18 |
$343.24 |
| In Buy Zone? |
No
|
Yes
|